Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

Movement Disorders

Volumn 17, Issue 1, 2002, Pages 145-149

  Fox, Susan H ^a   Kellett, Mark ^a,c   Moore, A Peter ^a   Crossman, Alan R ^b   Brotchie, Jonathan M ^b  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

Author keywords

Cannabis; Dystonia; Globus pallidus

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE; BOTULINUM TOXIN; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CHOLINERGIC RECEPTOR BLOCKING AGENT; COCODAMOL; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

4 AMINOBUTYRIC ACID UPTAKE; ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSTONIA; FEMALE; GLOBUS PALLIDUS; HUMAN; MALE; MEDICAL ASSESSMENT; NERVE ENDING; ORTHOSTATIC HYPOTENSION; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; SOMNOLENCE; TREATMENT FAILURE;

ADULT; AGED; ANTI-ANXIETY AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSTONIA; FEMALE; GLOBUS PALLIDUS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL;

EID: 0036460972     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1280     Document Type: Article

References (28)

1. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30: 277-282.
2. Crossman AR. An hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
3. Brotchie JM. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia. Adv Neurol 1999;80:71-85.
4. Lozano AM, Kumar R, Gross RE, Giladi N, Hutchison WD, Dostrovsky JO, Lang AE. Globus pallidus internus pallidotomy for generalised dystonia. Mov Disord 1997;12:865-870.
5. Lenz FA, Suarez JI, Metman LV, Reich SG, Karp BI, Hallett M, Rowland LH, Dougherty PM. Pallidal activity during dystonia: somatosensory reorganisation and changes with severity. J Neurol Neurosurg Psychiatry 1998;65:767-770.
6. Vitek JL, Chockkan V, Zhang JY, Kaneoke Y, Evatt M, DeLong MR, Triche S, Mewes K, Hashimoto T, Bakay RA. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 1999;46:22-35.
7. Ceballos-Baumann AO, Passingham RE, Warner T, Playford ED, Marsden CD, Brooks DJ. Overactive motor cortical areas in idiopathic dystoria. Ann Neurol 1995;37:363-372.
8. Mitchell IJ, Luquin R, Boyce S, Clarke CE, Robertson RG, Sambrook MA, Crossman AR. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 1990;5:49-54.
9. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992;115:809-824.
10. Matsumura Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995;65:59-70.
11. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87:1932-1936.
12. Herkenham M, Lynn AB, de CB, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991;547:267-274.
13. Glass M, Faull RL, Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 1993; 56:523-527.
14. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1988;36:189-261.
15. Pertwee RG, Greentree SG. Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology 1988;27:485-491.
16. Miller AS, Walker JM. Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. Eur J Pharmacol 1998;352:199-205.
17. Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996;308:161-164.
18. Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996;22:382-385.
19. Fahn S, Bressman S, Marsden CD. Classification of dystonia. In: Fahn S, Marsden CD, DeLong MR, editors. Dystoria 3, advances in neurology, vol. 78. Philadelphia: Lippincott-Raven; 1987. p 1-10.
20. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73-77.
21. Sieradzan K, Fox SH, Dick J, Brotchie JM. The effects of the cannabinoid receptor agonist, nabilone on L-DOPA-induced dyskinesia in patients with idiopathic Parkinson's disease. Mov Disord 1998;13(Suppl 2):1.035.
22. Fox SH, Kobylecki C, Begum S, et al. A role for cannabinoid receptor stimulation in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Mov Disord 1998;13(Suppl 2):2.032.
23. Ward A, Holmes B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1985;30:127-144.
24. Ahmedzai S, Carlyle IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983;48:657-663.
25. Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW. A single dose study of nabilone, a synthetic cannabinoid. Psychopharmacology (Berl) 1980;2:137-142.
26. Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW. Single-dose study of nabilone in anxious volunteers. J Clin Pharmacol 1981;8-9(Suppl):383S-396S.
27. Newell FW, Stark P, Jay WM, Schanzlin DJ. Nabilone: a pressure-reducing synthetic benzopyran in open-angle glaucoma. Ophthalmology 1979;1:156-160.
28. Rubin A, Lemberger L, Warrick P, et al. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 1977;1:85-91.